Core Viewpoint - Acumen Pharmaceuticals has secured a private placement of approximately $35.75 million to support its Enhanced Brain Delivery program for Alzheimer's disease treatment, reflecting strong investor confidence in its therapeutic approach targeting amyloid beta oligomers [1][2][3] Financing Details - The private placement involves the sale of shares at a price of $3.30 per share, with expected gross proceeds of around $35.75 million before expenses [1] - The transaction was led by RA Capital Management and included participation from other institutional investors [2] - The closing of the private placement is anticipated on or about March 16, 2026, pending customary closing conditions [3] Use of Proceeds - Proceeds from the financing will primarily support the Enhanced Brain Delivery (EBD) program, including preclinical development and working capital [3] - An Investigational New Drug (IND) submission for a lead clinical candidate is targeted for mid-2027 [3] Enhanced Brain Delivery Program - Acumen's EBD program utilizes JCR Pharmaceuticals' J-Brain Cargo technology to enhance drug delivery across the blood-brain barrier [9] - Preclinical data indicate that development candidates achieved 14-40 times higher brain levels in non-human primates compared to native antibodies, with low anemia risk and favorable stability profiles [7][8][10] - The program aims to develop a potential best-in-class treatment for Alzheimer's disease by combining amyloid beta oligomer-targeting antibodies with transferrin-receptor-targeting technology [10] Company Background - Acumen Pharmaceuticals is focused on developing therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease, with its lead candidate, sabirnetug (ACU193), currently in Phase 2 clinical trials [11] - The company collaborates with JCR Pharmaceuticals to advance its EBD therapy, leveraging proprietary drug delivery systems [11][12]

Core Viewpoint - Acumen Pharmaceuticals is advancing its research on sabirnetug, a novel therapeutic targeting soluble amyloid beta oligomers for Alzheimer's disease, with new data to be presented at the upcoming AD/PD conference [1][2]. Group 1: Conference Presentations - Acumen will present one oral and two poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases from March 17-21, 2026, in Copenhagen [1]. - The oral presentation will focus on enhanced brain delivery of sabirnetug in a mouse model of Alzheimer's disease [3]. - The poster presentations will cover biomarker treatment responses and the development of novel antibodies targeting amyloid beta oligomers [4]. Group 2: Research and Development - The oral presentation on enhanced brain delivery is part of a collaboration with JCR Pharmaceuticals, aiming to improve drug delivery to the brain and develop more effective treatment options for Alzheimer's disease [4]. - Sabirnetug (ACU193) is a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers, which are believed to be a significant factor in the neurodegenerative process of Alzheimer's disease [6]. - The ongoing Phase 2 clinical trial, ALTITUDE-AD, involves 542 participants and aims to evaluate the efficacy and safety of sabirnetug in slowing cognitive decline in early Alzheimer's disease [7]. Group 3: Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease, leveraging its expertise in amyloid beta oligomers [8]. - The company is also exploring a subcutaneous formulation of sabirnetug using Halozyme's ENHANZE drug delivery technology [8]. - Acumen's scientific founders have pioneered research on amyloid beta oligomers, which are increasingly recognized as early triggers of Alzheimer's pathology [8].